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Abstract
Laser interstitial thermal therapy is a minimally invasive ablative technique that continues 
to gain popularity in treatment of a variety of intracranial and spinal disorders. In the 
field of neuro-oncology it continues to be used for treatment of a variety of intracranial 
neoplasms, including glioblastoma—the most common malignant primary brain tumor. 
Maximizing the extent of resection in patients with glioblastoma was shown to prolong 
patient survival. Many patients present, however, with tumors that are nonresectable due 
to proximity to eloquent cortical or subcortical areas, or involvement of deep brain struc-
tures. LITT procedure, on the other hand, is minimally invasive and involves placing a 
laser catheter under stereotactic guidance and monitoring the size of the lesion produced 
as a result of laser ablation using MR thermography in real time. Therefore, a number of 
studies explored the potential of laser ablation to accomplish significant cytoreduction and 
thus potentially improve patient’s outcomes and prolong survival. The following chapter 
will review the principles of laser ablation and its current role in treatment of glioblastoma.
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1. Introduction
Laser interstitial thermal therapy (LITT) is a minimally invasive ablative technique that con-
tinues to gain popularity in a variety of domains of neurosurgery including neuro-oncology, 
epilepsy surgery, spine oncology and degenerative spine surgery, as well as chronic pain 
syndromes. In neuro-oncology, laser ablation is used for treatment of a variety of intracra-
nial neoplasms but used most frequently for treatment of recurrent brain metastases and 
radiation necrosis, as well as treatment of recurrent and newly diagnosed, difficult to access 
gliomas and other deep-seated tumors. The procedure involves placing a laser catheter 
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under stereotactic guidance, and the size of the lesion produced as a result of laser ablation is 
monitored using MR thermography in real time. The minimal invasiveness of the procedure 
makes it a good choice in patients that cannot tolerate a large operation due to either burden 
of disease or poor performance status.
Glioblastoma is a diffuse primary brain neoplasm with poor prognosis. The invasive nature 
and malignant potential of this tumor make its treatment a challenge. The current standard of 
care management paradigm consists of a multidisciplinary approach by combining maximal 
safe tumor resection with subsequent chemotherapy and radiation [1]. Despite maximal treat-
ment, survival rates of glioblastoma remain poor with median survival of 14–16 months. Recent 
evidence indicates, however, that the extent of resection of high-grade gliomas correlates with 
patient survival [2–6]. In a similar sense, laser ablation can provide effective tumor cytoreduction 
to maximize the effectiveness of adjuvant treatments. Furthermore, there is promising evidence 
that hyperthermia may have additional synergistic effects with radiation, as well as disrupt 
blood-brain barrier (BBB) and thus facilitate chemotherapy delivery to target tissues [7, 8].
The following chapter will focus on describing the principles of laser ablation and the equip-
ment used to deliver laser energy to brain tumors, as well as discussing current evidence for 
the use of laser thermal therapy in management of high-grade gliomas.
2. Background
2.1. The use of hyperthermia
The concept of using heat to destroy cancerous tissue has been attempted multiple times in 
the past. It was, however, difficult to develop a mechanism of heat delivery to the affected 
tissues that would allow controlled ablation of tissues in question. One of the earliest refer-
ences to the efficacy of mild hyperthermia in cancer destruction is found in 1891 in the report 
by Dr. Coley, an orthopedic surgeon, who made an observation of complete resolution of an 
inoperable sarcoma in a patient after Streptococcus pyogenes infection [9]. He suggested that 
the high fevers that accompany the illness injured cancer cells sufficiently to destroy them. 
He followed up that work by describing a series of 10 patients that were successfully treated 
with “bacterial toxin therapy” [9]. Unfortunately, his results were not reproduced by others.
In the years to come, radiation therapy and chemotherapy have established themselves as 
mainstream treatments for cancer. It was not until 1967 when Cavaliere et al. demonstrated 
selective sensitivity to heat of cancer cells, thus suggesting the use of hyperthermia as part 
of cancer therapy [10]. Follow-up work in animal models corroborated that notion. It was 
demonstrated that hyperthermia preferentially affects glioma cells compared to surrounding 
brain tissue. Local hypoxia and more acidic microenvironment within tumor contributes to 
this selective sensitivity to heat of glioblastoma [11]. Furthermore, hyperthermia potentiates 
the effects of radiation and chemotherapy observed in vitro [12–14].
Other factors, however, influence the effectiveness of hyperthermia. In vitro experiments 
showed that only 50% of sarcomas were responsive to hyperthermia resulting in tumor 
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remission, whereas the other 50% had no response to elevated temperatures [15]. The thresh-
old temperature at which irreversible damage occurs is different across species. While cell 
cycle arrest and increased cell death in rodent cell lines occurs at 43°C, in human cell lines 
that threshold is at 41°C [16].
The mechanism by which mild hyperthermia induces damage to cancer cells may involve 
activation of apoptosis pathways in a temperature dependent fashion, resulting in changes of 
expression of heat shock proteins such as HSP 27 and 72. The latter display antitumor proper-
ties by initiating immunologic response resulting in activation of natural killer cells directed 
against tumor cells [17].
2.2. Principles of laser thermal therapy
Laser interstitial therapy is an ablative technique that results in tissue destruction as a result 
of heating. Photons produced by the laser light are absorbed by the surrounding tissues caus-
ing excitation and release of excess energy as heat [18]. Once the critical thermal threshold is 
reached, protein denaturation and irreversible tissue coagulation ensues resulting in perma-
nent tissue damage.
The first lasers that were attempted for tissue ablation were ruby-based [19]. The amount 
of energy and thus tissue damage produced by these lasers was difficult to control. In 1983, 
Bown et al. first described the use of the neodymium-doped yttrium aluminum garnet 
(Nd:YAG) laser for tissue ablation [20]. At present, two commercially available FDA-approved 
systems are available for use in neurosurgery in the United States: The NeuroBlate System 
(Monteris Medical, Plymouth, MN) and the Visualase Thermal Therapy System (Medtronic 
Inc., Minneapolis, MN). Laser ablation uses laser energy in the near-infrared range where the 
main tissue interactions are heating and coagulation (as opposed to cutting for the CO
2
 laser). 
Both commercial laser ablation systems use diode lasers—one at the Nd:YAG wavelength 
(1064 nm) and the other at 980 nm. Although there have been claims that one is superior to 
the other, these are not founded in fact [21]. Lasers in this near-infrared range only penetrate 
a few millimeters into brain tissue. This heat is then propagated by conduction to allow for 
ablation radii that may extend up to 15–20 mm.
The wavelength of the laser light is what determines the efficiency of energy transfer to the 
tissues and, as a result, the volume of the lesion produced. Furthermore, the duration of tis-
sue exposure to the laser light affects the amount of energy transferred and thus the amount 
of heating produced, with longer duration of exposure resulting in higher temperatures 
achieved in exposed tissues [22–24]. The design of the optical fiber and the laser catheter 
further affects the properties of the laser. Initially, lasers had to be used at very low power 
(1–5 W) to avoid excessive heating that results in tissue charring. Improvement in laser cath-
eter design with the development of cooling mechanisms allowed use of higher power while 
still protecting nearby tissues. This also provides a non-stick catheter surface that allows the 
laser probe to glide easily through tissues. Current cooling systems employed in laser probe 
design use either cooled gas system with CO
2
, or a continuous flow of saline through a sheath 
surrounding the optic fiber.
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The laser probe tip is made of either sapphire or quartz to avoid altering the optical properties 
of the laser light. This design results in a spherical light distribution at the tip of the probe, and 
as a result, thermal energy is delivered in a symmetrical ellipsoid shape that is centered along 
the probe axis. The NeuroBlate System, in addition to the spherical probe design, also offers 
a side-firing probe which allows the surgeon to robotically control the direction of maximal 
heat distribution and may have an advantage in treating irregularly shaped lesions, or lesions 
near eloquent areas.
The Visualase system uses a 15 W 980 nm diode laser that is cooled with circulating sterile 
saline solution [25]. The diameter of the catheter is 1.65 mm. The laser probe tip comes with 
a light diffusing tip that results in spherical light distribution producing an ellipsoid area of 
tissue damage. This non-pulsed system produces faster lesions but the application of heat is 
limited to several minutes. The system is connected to a workstation that displays real-time 
thermography data as “thermal” and “damage” images [26, 27]. A number of safe points can 
be set on the pre-treatment MRI, and when the set temperature is reached at that point, the 
laser is deactivated.
The NeuroBlate System uses a 12 W solid-state Dornier diode laser that operates at Nd:YAG 
wavelength of 1064 nm [28]. The laser catheter is cooled with CO
2
 gas [29]. The probes come 
in two diameters: 3.2 and 2.2 mm. The light diffusing tip comes in two configurations: spheri-
cal, used to produce elliptical lesions along the probe axis, and side-firing probes, that enable 
treatment of complex and irregularly shaped lesions. The computer interface displays ther-
mal damage as thermal-damage-threshold (TDT) lines. The yellow line represents tissue vol-
ume that is exposed to the equivalent of 43°C for 2 min, the blue line is equivalent to exposure 
to 43°C for 10 min, and the white line surround the volume that received the equivalent of 
thermal energy of 43°C for 60 min. Based on the Arrhenius equation, the higher the tempera-
ture, the less time it takes to generate each TDT-line.
2.3. MR thermography
The use of laser ablation for treatment of tumors was first described by Bown in 1983 [20]. 
The first report of intracranial use for brain lesion laser ablation came out in 1990 [22]. Despite 
that, laser interstitial thermal therapy did not gain wide-spread use due to lack of the ability 
to monitor the extent of ablation and tissue damage. A variety of methods were attempted to 
measure thermal energy delivered to tissues and included skin thermometers, subcutaneous 
and interstitial probes, infrared detectors, and thermographic cameras, none of which were 
accurate enough to predict the size of the resulting thermal lesion [30–32]. Introduction of 
MR thermography revolutionized the application of laser thermal therapy since for the first 
time it allowed monitoring of the extent of tissue damage in real time [27]. The principle 
of MR thermography relies on detecting differential temperature-specific proton resonance 
frequency in the water molecules. At a given temperature, a proportion of water molecules 
are interconnected in space via hydrogen bonds between molecules. As the temperature of 
tissues increase during laser ablation, more water molecules are freed up from the hydrogen 
bonds between H
2
O molecules. During application of the magnetic field, proton nuclei within 
free water molecules are mobilized more effectively resulting in a different proton resonance 
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frequency, and this difference is used to interpolate local temperature using well defined rela-
tionship [18, 33]. MR thermography does not measure the actual temperature of tissue, rather 
the change in temperature over time, therefore an accurate core temperature is required at the 
start of each ablation. The Arrhenius model is then applied to estimate the degree of tissue 
damage that is produced based on the temperature and the amount of time that the tissues 
are exposed to a given temperature. Subsequently, computer software is used to visualize the 
temperature damage produced in real time with accurate temporal and special resolution.
2.4. Biological effect of LITT
Heating tissue results in different types of tissue damage. Several different zones of tissue 
damage have been described. Heating tissues to up to 40°C typically does not disrupt cellular 
homeostasis. Once the temperature increases in the range of 42–45°C, the cells display marked 
susceptibility to cellular damage [34]. This range is typically explored in hyperthermia experi-
ments. Further increase in temperature from 46 to 60°C results in significant cytotoxicity and 
consequent rapid cell death [35]. At temperatures exceeding 60°C, the damage sustained by 
mitochondrial enzymes, as well as cellular nucleic acids and proteins is so severe that coagu-
lative necrosis takes place [36]. Finally, heating tissues to near boiling temperatures results in 
charring, tissue evaporation and carbonization, that may result in life-threatening intracranial 
pressure increases if not immediately relieved. In addition to temperature thresholds, the 
length of time that the tissue exposed to a particular temperature determines the extent of tis-
sue damage with longer exposures resulting in equivalent damage that is observed at higher 
temperatures [18]. For instance, heating tissues to 43°C for 2 min will result in reversible tis-
sue damage. Whereas heating tissues to this temperature for 10 min will result in permanent 
injury, and for 60 min will result in coagulative necrosis.
As tissue heating occurs, concentric zones of damage can be identified [18, 37–39]. In the 
area around the fiber, the temperatures can reach high numbers in excess of 60°C resulting 
in central core area of coagulative necrosis. If the temperature in the area adjacent to the 
fiber inadvertently reaches 100°C, tissue vaporization occurs and a pseudocavity is formed. 
Immediately outside the core area lies the intermediate zone of permanently damaged tissue 
with increased interstitial fluid content. The outermost zone of damage that represents mar-
ginal zone consists of edematous but viable brain tissue. Histologically, the marginal zone is 
defined by lack of evidence of apoptosis and vessel thrombosis, and containing axonal swell-
ing, shrinking neurons, and hypertrophied endothelial cells—markers of reversible tissue 
injury. Following a laser ablation procedure, tissues typically exhibit an increase in size due to 
the presence of necrotic tissue and perilesional edema. Over time, however, the necrotic core 
of the lesion is replaced by granulation tissue resulting in lesion shrinkage and scar formation.
2.5. Radiographic appearance
The typical appearance of high grade glioma is an irregular and heterogeneously enhancing 
lesion on T1-weighted images. After treatment, there are typical changes that are observed on 
subsequent imaging studies [40–42]. Immediately after procedure one can appreciate an area 
of hyperintensity within the lesion on T1-weighted MRI images. This finding corresponds to 
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coagulated blood products within the ablated area. On the corresponding CT scans this would 
appear as a hyperdense area typical in appearance of blood products. With administration of 
contrast, there is typically an area of peripheral rim enhancement. This is thought to represent 
an area of sublethal tissue damage with disrupted blood-brain barrier and leaky capillaries [7].
3. Application of laser therapy for treatment of intracranial disease
3.1. Laser in glioma treatment
Since the first implementation of laser therapy for intracranial tissue ablation, treatment of a 
variety of intracranial lesions was attempted, including metastases, radiation necrosis, menin-
giomas, ependymomas, as well as gliomas. High grade gliomas constitute 14.9% of primary 
tumors brain tumors and 47.1% of all malignant primary brain and other CNS tumors. Despite 
maximal therapy, survival remains poor. Survival without any treatment is 9 weeks [43]. With 
maximal treatment according to the latest guidelines, the survival is prolonged to 14.6 months 
[1]. The combined use of radiation and temozolomide protocols increase survival rates to 27% 
at 2 years [1]. Recently, several retrospective studies have demonstrated that increasing the 
extent of resection of glioblastoma, improves patient survival [2–5]. Furthermore, intraopera-
tive use of surgical adjuncts such as intraoperative MRI or 5-ALA that allow visualization 
of the partially resected tumor and thus allow for a better extent of resection correlate with 
prolonged progression free survival [44, 45].
Many newly diagnosed glioblastomas involve deep or eloquent cortical or subcortical areas 
thus rendering these lesions difficult to resect or unresectable from an open surgery perspective. 
In these situations, the use of destructive, minimally invasive techniques such as LITT is very 
attractive as a means to cytoreduce the tumor. At other times patients may be too sick to undergo 
a lengthy open craniotomy for tumor resection. Finally, treatment of recurrent glioblastoma is 
challenging as very few effective options exist at present, thus the possibility of using laser abla-
tion for treatment of recurrent tumor ads another tool to the neurosurgeon’s armamentarium.
In 2013, the first human phase I study was published that used escalating dose of laser ther-
apy to assess safety of the procedure and its efficacy in controlling tumor growth in patients 
with recurrent high-grade gliomas [41]. The study recruited 11 patients from two institu-
tions and was completed using the NeuroBlate System. Three thermal damage threshold lines 
were assessed: yellow line (equivalent to heating of tissues to 43°C for 2 min), blue (43°C for 
10 min), and white (43°C for 60 min). Ultimately, ten patients underwent LITT treatments 
and were followed for a minimum of 6 months or until death. Initially three patients were 
treated to the yellow TDT line and followed for 14 days to assess for signs of toxicity. If two 
out of three patients developed signs of toxicity, no further dose escalation was performed. If 
no toxicity was observed, the dose of treatment was escalated to first the blue line, and then 
the white line. The mean size of treated tumors was 6.8 cm3, and an average of 78% of total 
tumor volume was covered. Median overall survival was 10.5 months after LITT which was 
increased compared to historic controls of 3–9 months [46, 47]. The median PFS at 6 months 
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and median overall survival in the study was >30%. One patient had a new permanent post-
operative neurological deficit, and one patient had a vascular injury resulting in a pseudoa-
neurysm. Both patients were in the white TDT line subgroup. This study demonstrated that 
LITT is a feasible and safe treatment modality for recurrent high-grade gliomas, and that the 
blue line should be used as the margin of treated area.
The first multicenter study to investigate whether cytoreduction achieved with the use of 
laser for difficult to access high-grade gliomas could have a similar survival benefit com-
pared to surgery was a retrospective study that looked at outcomes in 34 patients with high 
grade gliomas that were treated with LITT, 19 of them treated upfront, and 16 patients as 
salvage therapy [48]. The median overall survival was not reached in the study. One year 
estimated overall survival was 68%, and median progression free survival was 5.1 months. 
They also demonstrated that increased coverage by the thermal damage threshold lines cor-
related with better progression free survival of 9.7 vs. 4.6 months. The latter also relates to 
tumor volume with smaller tumors being easier to achieve complete coverage with TDT lines. 
When looking at failure patterns, 5 tumors recurred within the treatment field, 12 patients 
recurred at the periphery of the treated volume, 5 tumors recurred within 2 cm of the original 
area of enhancement, and one case had a remote recurrence. Overall, the authors concluded 
that LITT is an effective treatment modality for newly diagnosed and recurrent high-grade 
gliomas with improved outcomes correlating with extent of tumor coverage by analogy with 
extent of resection in surgical series.
Recently, a meta-analysis of the efficacy of LITT treatment of newly diagnosed and recurrent 
high-grade gliomas was published [49]. Ivan et al. extracted information and analyzed the data 
pertaining to treatment and outcomes of newly diagnosed high-grade gliomas treated with 
LITT. They identified four articles that reported treatment of 25 patients with newly identified 
gliomas. Tumor volume was available for 22 patients and the mean was 16.5 cm3, whereas the 
extent of volume treated with laser was available for 9 patients with an average of 82.9% tumor 
coverage. Complications data was available for 13 patients, and there were no intraoperative 
mortality or complications. Serious postoperative complications occurred in two patients, one 
succumbing to postoperative central nervous system infection, and another one requiring 
hemicraniectomy for malignant post treatment cerebral edema. No permanent new postopera-
tive neurological complications were noticed among these patients. Outcome analysis revealed 
a mean follow up of 7.6 months, with 12 patients still followed or lost to follow-up. Median 
overall survival was 14.2 months and the average PFS was 5.1 months. These results are similar 
to results reported in the literature that vary from 8.5 to 14.5 months [50, 51]. Thus, this sys-
tematic review demonstrates that LITT is a safe and effective procedure for newly diagnosed 
high-grade gliomas achieving outcomes similar to cases with open surgical resection.
Even with the full complement of modern treatments, the survival of glioblastoma patients 
remains poor in the range of 14–16 months after surgery, chemotherapy and radiation. 
Recurrence is the rule rather than the exception, at which point the prognosis is quite poor 
with the 6-month progression free survival rates of 5–15% [52, 53]. Reoperation in the recur-
rent setting was shown to be of benefit [54]. The risk of complications needs to be weighed 
against potential survival benefit, which is where the role for the use of LITT in recurrent 
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high-grade gliomas could be exploited the most. A recent systematic review summarized 
the outcomes of laser-mediated cytoreduction in high-grade gliomas [55]. Six articles were 
identified that included outcome analysis for treatment of 64 lesions in 63 patients. The range 
of pre-treatment tumor volumes was from 0.37 cm3 to 68.9 cm3. Postoperatively, serious com-
plications included a permanent neurological deficit in 7 patients (12%), vascular injuries in 
3 patients (3%), and wound infection in 1 patient (2%). The authors did not comment on 
outcome measures due to differences in outcome metrics used in the studies. Thus, they con-
cluded that currently there is insufficient evidence to recommend LITT for treatment of recur-
rent high-grade gliomas. It is a technique that allows safe and accurate ablation of tumor 
tissue, though the complication rate associated with this procedure remains around 15% that 
is similar to open craniotomy procedures [56, 57].
3.2. Laser ablation near eloquent areas
The most common complication reported after laser ablation is a temporary or permanent 
neurological deficit, such as hemiparesis or aphasia. The reported complication rates range 
from 0 to 29.4% for transient and 0–10% for permanent postoperative neurological deficits. 
In many instances it is the damage to subcortical tracts that results in a new deficit. Recently, 
diffusion weighted imaging (DTI) with fiber-tracking algorithms started to be increasingly 
used in tumor resection surgery to avoid injury to eloquent white matter tracts. A recent 
study investigated the role of integration of DTI fiber tracts in laser thermal therapy. Using 
the NeuroBlate System, Sharma et al. looked that the extent of the overlap of the thermal 
damage threshold lines with the cortical fibers that would result in a postoperative motor 
deficit [58]. Retrospective analysis of 80 patients who underwent LITT for tumor near a 
critical area was performed. Fourteen patients (17.5%) had developed a new postoperative 
deficit that was temporary in 3 patients and permanent in 11. When looking at the average 
volume or surface overlap between treated area and the corticospinal fibers, there was a sig-
nificant difference between the group that developed a postoperative deficit and the group 
that did not. Therefore, even a minimal overlap between the treated area enclosed within 
thermal damage treatment lines and the descending motor fibers can cause a postoperative 
neurological deficit after laser ablation. Addition of DTI tractography to treatment plans 
of lesions located in proximity to eloquent areas can help avoid fiber damage and thus 
preserve neurological functioning of the patient and is routinely used in our ablations near 
critical subcortical fiber tracts.
3.3. Advantages of LITT
There are a number of characteristics of LITT that lead to its recent popularity and investiga-
tion for multiple applications in neurosurgery. The main one is the ability to produce a lesion 
in a location that is difficult to access with open surgery. It is a minimally invasive technique 
that requires a very small incision and subsequently a very short period of healing. Given the 
minimally invasive nature of the procedure, the operation can be done under local anesthesia 
in a cooperative patient. This allows treatment of lesions in patients that cannot otherwise 
tolerate a large craniotomy.
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Furthermore, LITT is a thermal ablating technique, which means that at the time of tumor 
recurrence the procedure can be repeated. That is not always the case with ionizing radiation, 
for example, since there is cumulative accumulation of radiation dose that limits the number 
of treatments that can be safely offered. The procedure also offers the advantage of obtaining 
a tissue specimen, when combined with needle biopsy, for updated pathology and biomark-
ers to follow tumor evolution and response to therapy. Finally, the minimally invasive nature 
of the procedure allows continued use of adjuvant treatments around the time of the surgery, 
or very shortly thereafter, obviating the need of waiting at least 2–3 weeks for the tissues to 
heal before restarting chemotherapy of radiation. In fact, there is evidence that LITT may 
open up the blood-brain barrier in the vicinity of treatment area, thus enhancing delivery of 
chemotherapeutics in that time range [7].
3.4. LITT and blood-brain barrier
The blood-brain barrier (BBB) is one of the main challenges for chemotherapy delivery to 
brain tumors. Various methods have been attempted to bypass or disrupt the blood-brain 
barrier, including convection-enhanced delivery of implanted catheters into the tumor, intra-
arterial mannitol injections, or focused ultrasound to temporally disrupt the blood-brain bar-
rier. Recently, laser interstitial thermal therapy was implicated in disrupting the integrity 
of tumor endothelial cells post-treatment. The core of the lesion that is produced after laser 
ablation is coagulum that consists of a permanently damaged tissue, whereas at the periphery 
where the temperature reaches 40°C and is insufficient to result in cell death, however it does 
lead to physiological temporary disruption in cellular function resulting in transient disrup-
tion of the BBB. Imaging of the lesion after laser ablation therapy displays an area of periph-
eral contrast enhancement that was speculated to represent disruption of the blood-brain 
barrier. This was demonstrated in a rodent model where there was extravasation of Evans 
blue dye that was injected intravenously at the periphery of the lesion post ablation [59].
Recently, advanced MRI imaging was used to demonstrate the presence of blood-brain bar-
rier disruption [7]. Dynamic contrast-enhanced MRI was used in 14 patients to determine 
transfer coefficients (Ktrans) as a measure of permeability at the periphery of the lesion pro-
duced by laser ablation. In all patients, Ktrans coefficient peaked after the procedure, and then 
declined gradually over the next 4 weeks. The authors also used brain specific enolase (BSE) 
serum levels as a marker of BBB breakdown, and those levels peaked at about 3 weeks, fol-
lowed by gradual decline and normalization at 6 weeks. This data suggests that there is some 
breakdown of the blood-brain barrier in the first few weeks following laser ablation of pri-
mary brain tumors, and that this may facilitate chemotherapy delivery to residual infiltrated 
tumor in the immediate post-procedure period.
3.5. Sensitization to radiation
Radiation is one of the non-surgical modalities that has significant impact on survival in glio-
blastoma patients, yet the control rates remain poor despite maximal therapy. Several studies 
have demonstrated the synergistic effect of hyperthermia in sensitizing tumor tissues to radia-
tion and improved tumor control [60–62]. A recent study investigated the mechanism by which 
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thermotherapy affects tumor cells that results in enhanced sensitivity to radiation [8]. Glioma 
stem cell (GSC) cultures and mice bearing glioma xenographs were first exposed to 42°C for 
1 h followed by radiation. When compared to radiation or hyperthermia alone, glioma stem 
cells are most significantly affected when both modalities are used in combination. Exposure 
of GSC to heat and radiation reduced stem cell survival, proliferation, and DNA repair, as 
well as promoted cell death. On the molecular level, there was significantly less AKT phos-
phorylation in cells exposed to hyperthermia and radiation, and rescuing AKT phosphoryla-
tion levels reversed negative effects of heat and radiation maintaining viability of tumor stem 
cells. Furthermore, exposing the mice bearing glioma xenographs to hyperthermia and radia-
tion consistently reduced tumor size in these animals, and significantly increased their sur-
vival compared to animals exposed to either hyperthermia or radiation alone. These results 
add further evidence that the addition of hyperthermia to the standard radiation treatment 
may have a significant additive effect with respect to tumor control that is mediated by altering 
phosphorylation levels of PI3K-AKT pathway. Thus, early radiation therapy after laser abla-
tion procedure may have additive effect on controlling tumor growth and affecting glioma cell 
viability. Further studies are needed to explore the clinical potential of this combined treatment.
4. Representative cases
4.1. Patient 1
The first patient is a 48-year-old right handed gentleman who presented to hospital after sus-
taining a fall. A CT head was performed that revealed a 1.9 × 2.0 cm ring-enhancing lesion in 
the left cingulum with significant amount of surrounding edema (Figure 1). On initial evalu-
ation, patient had 4/5 right hand weakness and right-sided pronator drift that improved with 
initiation of steroids. The lesion was located immediately below the paracentral lobule, and 
given its proximity to this eloquent area, a needle biopsy with subsequent laser ablation was 
offered to the patient, who agreed to proceed. The lesion was treated using two trajectories 
using a side-firing laser (Monteris) to ensure the full tumor volume was included within blue 
thermal threshold treatment lines. Postoperatively, his neurological exam remained stable 
with the exception of the transient neglect of right lower extremity. Pathology of the tumor 
was consistent with glioblastoma. Molecular analysis demonstrated negative staining for 
IDH-1 and p53, intact 1p/19q, and non-amplified EGFR. Proliferative index was moderate 
with Ki-67 about 9–10%. The patient underwent subsequent concurrent chemotherapy and 
radiation according to the Stupp protocol followed by twenty-two cycles of temozolomide. 
Following that, he was followed with regular MRI brain scans that demonstrated a significant 
decrease in the size of the lesion over the first 12 months. It remains stable without evidence 
of recurrence or progression 6 years after the initial procedure (Figure 1).
4.2. Patient 2
The second patient is a 66-year-old right handed woman who was evaluated for spells of diz-
ziness and visual disturbance. Brain imaging demonstrated a homogenously enhancing right 
parahippocampal lesion measuring 1.2 × 0.9 cm with surrounding edema (Figure 2). Patient 
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Figure 1. Representative axial T1-weighted MRI images obtained post gadolinium contrast administration. (A) 
Preoperative; (B) at 24 h post laser ablation; (C) at 3 months; (D) at 1 year; and (E) at 6 years post laser ablation; (F) a 
corresponding T2 weighted axial slice demonstrating very limited amount of edema surrounding the lesion.
Figure 2. Representative MRI images of the right temporal lesion of patient 2. Axial T1-weighted MR images following 
contrast administration. The patient originally presented with a right mesial homogenously enhancing lesion (A). 
Immediately following laser ablation the characteristics of the lesion changed with markedly less contrast uptake (B). 
In the subsequent months, the lesion has continued to involute and significantly decreased in size at 3 months (C), and 
almost disappeared completely at 2.5 years (D).
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was started on Keppra. Laser ablation of the lesion with a concurrent biopsy was recom-
mended given the deep-seated location of the tumor. A single trajectory was used employ-
ing a side firing laser (Monteris). Complete tumor coverage was achieved as indicated by 
inclusion of the entire tumor volume within the blue thermal damage threshold lines. She 
had an uneventful postoperative course. No new postoperative deficits were associated with 
the procedure. Pathology showed a hypercellular glial tumor with marked nuclear atypia, 
frequent mitoses, and vascular proliferative changes, consistent with the diagnosis of glio-
blastoma. A Ki-67 labeling index in excess of 30% was focally noted. Greater than 80% of 
tumor cells stained positively with antibody to p53. 1p/19q chromosomes were intact, and 
EGFR was non-amplified. Following laser treatment, the patient received chemotherapy and 
radiation according to Stupp protocol, followed by adjuvant temozolomide for eight cycles 
that was stopped due to persistent myelosuppression. She was followed with regular MRI 
scans of brain with great local control with nearly complete resolution of the treated lesion. 
Unfortunately, at 2.5 years after procedure she developed disease progression at a remote site.
5. Conclusion
Laser thermal therapy is an effective treatment modality for newly diagnosed and recurrent 
gliomas. It may act in conjunction with radiation thus potentiating the effects of radiation. 
In addition, it may result in transient disruption of blood-brain barrier in the area of treat-
ment and thus facilitate chemotherapy delivery postoperatively. Further studies examining 
the outcomes of new and recurrent glioma treatment would help to define the role that laser 
ablation play in management of this devastating brain tumor.
Author details
Daria Krivosheya, Hamid Borghei-Razavi, Gene H. Barnett and Alireza M. Mohammadi*
*Address all correspondence to: mohamma3@ccf.org
Department of Neurological Surgery, Rose Ella Burkhardt Brain Tumor and  
Neuro-Oncology Center, Cleveland Clinic CA-51, Cleveland, OH, United States
References
[1] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adju-
vant temozolomide for glioblastoma. The New England Journal of Medicine. 2005; 
352(10):987-996
[2] Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients 
with glioblastoma multiforme: Prognosis, extent of resection, and survival. Journal of 
Neurosurgery. 2001;95(2):190-198
Glioma - Contemporary Diagnostic and Therapeutic Approaches198
[3] McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa 
A. Association of surgically acquired motor and language deficits on overall survival 
after resection of glioblastoma multiforme. Neurosurgery [Internet]. 2009;65(3):463-469, 
discussion 469-70. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi
?dbfrom=pubmed&id=19687690&retmode=ref&cmd=prlinks
[4] Sanai N, Polley M-Y, McDermott MW, Parsa AT, berger MS. An extent of resection 
threshold for newly diagnosed glioblastomas. Journal of Neurosurgery. 2011;115(1):3-8
[5] Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual 
contrast enhancement on initial surgery as predictors of outcome in adult patients with 
hemispheric anaplastic astrocytoma. Journal of Neurosurgery. 2006;105(1):34-40
[6] Stummer W, Reulen H-J, Meinel T, et al. Extent of resection and survival in glioblastoma 
multiforme: Identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576, 
discussion 564-76
[7] Leuthardt EC, Duan C, Kim MJ, et al. Hyperthermic laser ablation of recurrent Glio-
blastoma leads to temporary disruption of the Peritumoral blood brain barrier. PLoS 
One. 2016;11(2):e0148613
[8] Man J, Shoemake JD, Ma T, et al. Hyperthermia sensitizes glioma stem-like cells to radia-
tion by inhibiting AKT signaling. Cancer Research. 2015;75(8):1760-1769
[9] Coley WB. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins 
of the Streptococcus erysipelas and the Bacillus prodigiosus). Proceedings of the Royal 
Society of Medicine. 1910;3(Surg Sect):1-48
[10] Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. 
Biochemical and clinical studies. Cancer. 1967;20(9):1351-1381
[11] Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response 
of malignant cells in vitro. Radiology. 1977;123(2):511-514
[12] Watanabe M, Tanaka R, Hondo H, Kuroki M. Effects of antineoplastic agents and hyper-
thermia on cytotoxicity toward chronically hypoxic glioma cells. International Journal of 
Hyperthermia. 1992;8(1):131-138
[13] Dewey WC, Freeman ML. Rationale for use of hyperthermia in cancer therapy. Annals 
of the New York Academy of Sciences. 1980;335:372-378
[14] Robinson JE, Wizenberg MJ, McCready WA. Combined hyperthermia and radiation 
suggest an alternative to heavy particle therapy for reduced oxygen enhancement ratios. 
Nature. 1974;251(5475):521-522
[15] Mueller-Klieser W, Walenta S, Kelleher DK, Dinh H, Marx E, Vaupel P. Tumour-growth 
inhibition by induced hyperglycaemia/hyperlactacidaemia and localized hyperthermia. 
International Journal of Hyperthermia. 1996;12(4):501-511
[16] Armour EP, McEachern D, Wang Z, Corry PM, Martinez A. Sensitivity of human cells to 
mild hyperthermia. Cancer Research. 1993;53(12):2740-2744
Laser Interstitial Thermal Therapy in Glioblastoma
http://dx.doi.org/10.5772/intechopen.77078
199
[17] Elsner L, Muppala V, Gehrmann M, et al. The heat shock protein HSP70 promotes 
mouse NK cell activity against tumors that express inducible NKG2D ligands. Journal 
of Immunology. 2007;179(8):5523-5533
[18] Stafford RJ, Fuentes D, Elliott AA, Weinberg JS, Ahrar K. Laser-induced thermal therapy 
for tumor ablation. Critical Reviews in Biomedical Engineering. 2010;38(1):79-100
[19] Rosomoff HL, Carroll F. Reaction of neoplasm and brain to laser. Archives of Neurology. 
1966;14(2):143-148
[20] Bown SG. Phototherapy in tumors. World Journal of Surgery. 1983;7(6):700-709
[21] Jethwa PR, Barrese JC, Gowda A, Shetty A, Danish SF. Magnetic resonance thermome-
try-guided laser-induced thermal therapy for intracranial neoplasms: Initial experience. 
Neurosurgery. 2012;71(1 Suppl Operative):133-144, 144-5
[22] Sugiyama K, Sakai T, Fujishima I, Ryu H, Uemura K, Yokoyama T. Stereotactic intersti-
tial laser-hyperthermia using Nd-YAG laser. Stereotactic and Functional Neurosurgery. 
1990;54-55(1-8):501-505
[23] Ascher PW, Justich E, Schröttner O. A new surgical but less invasive treatment of cen-
tral brain tumours preliminary report. Acta Neurochirurgica. Supplementum (Wien). 
1991;52:78-80
[24] Rahmathulla G, Recinos PF, Kamian K, Mohammadi AM, Ahluwalia MS, Barnett 
GH. MRI-guided laser interstitial thermal therapy in neuro-oncology: A review of its 
current clinical applications. Oncology. 2014;87(2):67-82
[25] Carpentier A, Itzcovitz J, Payen D, et al. Real-time magnetic resonance-guided laser 
thermal therapy for focal metastatic brain tumors. Operative Neurosurgery. 2008; 
63:ONS21-ONS29
[26] Torres-Reveron J, Tomasiewicz HC, Shetty A, Amankulor NM, Chiang VL. Stereotactic 
laser induced thermotherapy (LITT): A novel treatment for brain lesions regrowing after 
radiosurgery. Journal of Neuro-Oncology. 2013;113(3):495-503
[27] Chen L, Wansapura JP, Heit G, Butts K. Study of laser ablation in the in vivo rabbit brain 
with MR thermometry. Journal of Magnetic Resonance Imaging. 2002;16(2):147-152
[28] Mohammadi AM, Schroeder JL. Laser interstitial thermal therapy in treatment of brain 
tumors—The NeuroBlate System. Expert Review of Medical Devices. 2014;11(2):109-119
[29] Sharma M, Balasubramanian S, Silva D, Barnett GH, Mohammadi AM. Laser intersti-
tial thermal therapy in the management of brain metastasis and radiation necrosis after 
radiosurgery: An overview. Expert Review of Neurotherapeutics. 2016;16(2):223-232
[30] Cheng MK, McKean J, Boisvert D, Tulip J, Mielke BW. Effects of photoradiation therapy 
on normal rat brain. Neurosurgery. 1984;15(6):804-810
[31] Elias Z, Powers SK, Atstupenas E, Brown JT. Hyperthermia from interstitial laser irradia-
tion in normal rat brain. Lasers in Surgery and Medicine. 1987;7(4):370-375
Glioma - Contemporary Diagnostic and Therapeutic Approaches200
[32] Marchesini R, Andreola S, Emanuelli H, et al. Temperature rise in biological tissue dur-
ing Nd:YAG laser irradiation. Lasers in Surgery and Medicine. 1985;5(2):75-82
[33] McNichols RJ, Gowda A, Kangasniemi M, Bankson JA, Price RE, Hazle JD. MR ther-
mometry-based feedback control of laser interstitial thermal therapy at 980 nm. Lasers 
in Surgery and Medicine. 2004;34(1):48-55
[34] Horsman MR, Overgaard J. Hyperthermia: A potent enhancer of radiotherapy. Clinical 
Oncology (Royal College of Radiologists). 2007;19(6):418-426
[35] Larson TR, Bostwick DG, Corica A. Temperature-correlated histopathologic changes fol-
lowing microwave thermoablation of obstructive tissue in patients with benign prostatic 
hyperplasia. Urology. 1996;47(4):463-469
[36] Thomsen S. Pathologic analysis of photothermal and photomechanical effects of laser-
tissue interactions. Photochemistry and Photobiology. 1991;53(6):825-835
[37] Boyes A, Tang K, Yaffe M, Sugar L, Chopra R, Bronskill M. Prostate tissue analysis imme-
diately following magnetic resonance imaging guided transurethral ultrasound thermal 
therapy. The Journal of Urology. 2007;178(3 Pt 1):1080-1085
[38] Hazle JD, Diederich CJ, Kangasniemi M, Price RE, Olsson LE, Stafford RJ. MRI-
guided thermal therapy of transplanted tumors in the canine prostate using a direc-
tional transurethral ultrasound applicator. Journal of Magnetic Resonance Imaging. 
2002;15(4):409-417
[39] Stafford RJ, Shetty A, Elliott AM, et al. Magnetic resonance guided, focal laser induced 
interstitial thermal therapy in a canine prostate model. The Journal of Urology. 2010; 
184(4):1514-1520
[40] Rahmathulla G, Recinos PF, Valerio JE, Chao S, Barnett GH. Laser interstitial ther-
mal therapy for focal cerebral radiation necrosis: A case report and literature review. 
Stereotactic and Functional Neurosurgery. 2012;90(3):192-200
[41] Sloan AE, Ahluwalia MS, Valerio-Pascua J, et al. Results of the NeuroBlate System first-
in-humans phase I clinical trial for recurrent glioblastoma: Clinical article. Journal of 
Neurosurgery. 2013;118(6):1202-1219
[42] Patel NV, Jethwa PR, Barrese JC, Hargreaves EL, Danish SF. Volumetric trends asso-
ciated with MRI-guided laser-induced thermal therapy (LITT) for intracranial tumors. 
Lasers in Surgery and Medicine. 2013;45(6):362-369
[43] Fazeny-Dörner B, Wenzel C, Veitl M, et al. Survival and prognostic factors of patients 
with unresectable glioblastoma multiforme. Anti-Cancer Drugs. 2003;14(4):305-312
[44] Kubben PL, Meulen ter KJ, Schijns OEMG, Laak-Poort ter MP, van Overbeeke JJ, van 
Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: A sys-
tematic review. The Lancet Oncology. 2011;12(11):1062-1070
[45] Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V. Intraoperative MRI guidance 
and extent of resection in glioma surgery: A randomised, controlled trial. The Lancet 
Oncology. 2011;12(11):997-1003
Laser Interstitial Thermal Therapy in Glioblastoma
http://dx.doi.org/10.5772/intechopen.77078
201
[46] Barker FG, Chang SM, Gutin PH, et al. Survival and functional status after resection of 
recurrent glioblastoma multiforme. Neurosurgery. 1998;42(4):709-720, discussion 720-3
[47] Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with 
irinotecan in recurrent glioblastoma. Journal of Clinical Oncology. 2009;27(28):4733-4740
[48] Mohammadi AM, Hawasli AH, Rodriguez A, et al. The role of laser interstitial thermal 
therapy in enhancing progression-free survival of difficult-to-access high-grade glio-
mas: A multicenter study. Cancer Medicine. 2014;3(4):971-979
[49] Ivan ME, Mohammadi AM, De Deugd N, et al. Laser ablation of newly diagnosed malig-
nant gliomas. Neurosurgery. 2016;79:S17-S23
[50] Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with 
glioblastoma: Recursive partitioning analysis. Neuro-Oncology. 2004;6(3):227-235
[51] Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic fac-
tors for recently diagnosed malignant glioma: Data from the glioma outcomes project. 
Journal of Neurosurgery. 2003;99(3):467-473
[52] Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progres-
sion-free survival and 12-month overall survival end points for phase II trials in patients 
with glioblastoma multiforme. Neuro-Oncology. 2007;9(1):29-38
[53] Lamborn KR, Yung WKA, Chang SM, et al. Progression-free survival: An important 
end point in evaluating therapy for recurrent high-grade gliomas. Neuro-Oncology. 
2008;10(2):162-170
[54] McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection 
with survival in patients with malignant brain astrocytoma. Journal of Neurosurgery. 
2009;110(1):156-162
[55] Lee I, Kalkanis S, Hadjipanayis CG. Stereotactic laser interstitial thermal therapy for 
recurrent high-grade Gliomas. Neurosurgery. 2016;79(Suppl 1):S24-S34
[56] Senders JT, Muskens IS, Cote DJ, et al. Thirty-day outcomes after craniotomy for pri-
mary malignant brain tumors: A national surgical quality improvement program analy-
sis. Neurosurgery. 2018;18(suppl_5):v1
[57] Malone H, Cloney M, Yang J, et al. Failure to rescue and mortality following resection of 
intracranial neoplasms. Neurosurgery. 2017;364(22):2128
[58] Sharma M, Habboub G, Behbahani M, Silva D, Barnett GH, Mohammadi AM. Thermal 
injury to corticospinal tracts and postoperative motor deficits after laser interstitial ther-
mal therapy. Neurosurgical Focus. 2016;41(4):E6-E9
[59] Sabel M, Rommel F, Kondakci M, Gorol M, Willers R, Bilzer T. Locoregional opening 
of the rodent blood-brain barrier for paclitaxel using Nd:YAG laser-induced thermo 
therapy: A new concept of adjuvant glioma therapy? Lasers in Surgery and Medicine. 
2003;33(2):75-80
Glioma - Contemporary Diagnostic and Therapeutic Approaches202
[60] Man J, Shoemake J, Zhou W, et al. Sema3C promotes the survival and tumorigenicity of 
glioma stem cells through Rac1 activation. Cell Reports. 2014;9(5):1812-1826
[61] Jones EL, Oleson JR, Prosnitz LR, et al. Randomized trial of hyperthermia and radiation 
for superficial tumors. Journal of Clinical Oncology. 2005;23(13):3079-3085
[62] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia 
as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European 
Society for Hyperthermic Oncology. Lancet. 1995;345(8949):540-543
Laser Interstitial Thermal Therapy in Glioblastoma
http://dx.doi.org/10.5772/intechopen.77078
203

